Tag: IDH1 inhibitor therapy

Home / IDH1 inhibitor therapy

Categories

Ivosidenib is approved by FDA for myelodysplastic syndromes

Nov 2023: The Food and Drug Administration (FDA) approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in November 2023 for the treatment of adult patients with relapsed or refractory myelod...
idh1-inhibitor-therapy